- Condition: Rheumatoid Arthritis
Interventions: Drug: VX-509; Drug: VX-509 matching placebo
Sponsors: Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: fostamatinib; Drug: placebo
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified April 2012 - Conditions: Osteoarthritis; Traumatic Arthritis; Total Knee Joint Prosthesis
Intervention: Device: 3DKnee™ System with Vitamin E UHMWPE Tibial Inserts
Sponsors: Encore Medical, L.P.; Encore Medical, L.P.; DJO Incorporated
Recruiting - verified May 2012 - Condition: Osteoarthritis of the Knee
Interventions: Drug: AF-219; Drug: Sugar Pill
Sponsors: Afferent Pharmaceuticals, Inc.; Afferent Pharmaceuticals, Inc.
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Biological: PF-05280586; Biological: MabThera; Biological: Rituxan
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Biological: Certolizumab Pegol + Methotrexate (MTX); Biological: Placebo + Methotrexate (MTX)
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2012 - Condition: Tophaceous Gout
Interventions: Drug: Lesinurad; Drug: Lesinurad; Drug: Placebo
Sponsors: Ardea Biosciences, Inc.; Ardea Biosciences, Inc.
Recruiting - verified March 2012 - Condition: Gout
Interventions: Drug: Lesinurad; Drug: Lesinurad; Drug: Placebo
Sponsors: Ardea Biosciences, Inc.; Ardea Biosciences, Inc.
Recruiting - verified May 2012 - Condition: Gout
Interventions: Drug: lesinurad; Drug: Placebo
Sponsors: Ardea Biosciences, Inc.; Ardea Biosciences, Inc.
Recruiting - verified May 2012 - Condition: Gout
Interventions: Drug: Lesinurad; Drug: Lesinurad; Drug: Placebo
Sponsors: Ardea Biosciences, Inc.; Ardea Biosciences, Inc.
Recruiting - verified May 2012 - Condition: Chronic Gout
Intervention: Biological: pegloticase
Sponsors: Savient Pharmaceuticals; Savient Pharmaceuticals
Recruiting - verified May 2012 - Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout FlaresCondition: Gout
Interventions: Drug: Rilonacept; Drug: Placebo; Drug: Allopurinol
Sponsors: Regeneron Pharmaceuticals; Regeneron Pharmaceuticals
Recruiting - verified January 2012 - Condition: Intercritical Gout
Interventions: Drug: Colchicine; Drug: Placebo; Drug: Allopurinol
Sponsors: Regeneron Pharmaceuticals; Regeneron Pharmaceuticals
Recruiting - verified April 2012 - Condition: Acute Gouty Arthritis
Intervention: Drug: Canakinumab 150mg in prefilled syringe
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Chronic Gouty Arthritis
Intervention: Biological: canakinumab
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified November 2011 - Condition: Rheumatoid Arthritis
Interventions: Drug: MRC375; Drug: Matching Placebo; Drug: MRC375 150mg
Sponsors: Molecular Research Center, Inc.; Molecular Research Center, Inc.; Camargo Pharmaceutical Services; Rho; Clin Data Services; Harrison Clinical Research; BARC Global Central Laboratory; Bilcare Global Clinical Supplies
Recruiting - verified January 2012 - Condition: Gout
Intervention: Drug: Allopurinol
Sponsors: Ardea Biosciences, Inc.; Ardea Biosciences, Inc.
Recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: rituximab [MabThera/Rituxan]; Drug: methotrexate
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: PF-04171327; Drug: PF-04171327; Drug: PF-04171327; Drug: PF-04171327; Drug: prednisone; Other: prednisone; Other: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: BMS-945429 Placebo; Biological: BMS-945429; Biological: BMS-945429; Biological: BMS-945429; Biological: BMS-945429; Drug: Methotrexate; Drug: Methotrexate; Drug: Methotrexate Placebo; Drug: Methotrexate; Drug: Adalimumab Placebo; Drug: Adalimumab
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified January 2012 - Condition: Rheumatoid Arthritis
Interventions: Biological: secukinumab; Biological: secukinumab; Biological: placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Acute Gouty Arthritis
Interventions: Drug: Canakinumab pre-filled syringe; Drug: Canakinumab lyophilized cake; Drug: Triamcinolone Acetonide
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Cardiovascular Disease, Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: etanercept
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified March 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: adalimumab; Drug: Placebo; Drug: Placebo; Drug: methotrexate; Drug: folate
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: Fostamatinib and placebo injections; Drug: Fostamatinib and placebo injections; Drug: Fostamatinib and placebo injections; Drug: Adalimumab and placebo of fostamatinib; Drug: Placebo of fostamatinib, fostamatinib, and placebo injections
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified March 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: Fostamatinib; Drug: Fostamatinib; Drug: Fostamatinib
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified March 2012 - Condition: Rheumatoid Arthritis
Intervention: Drug: LY2127399
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Arthritis, Rheumatoid
Interventions: Drug: Part 1: Etoricoxib 60 mg; Drug: Part 1: Etoricoxib 90 mg; Drug: Part 2: Etoricoxib 60 mg; Drug: Part 2: Etoricoxib 90 mg; Drug: Part 1: Placebo to Etoricoxib 60 mg; Drug: Part 1: Placebo to Etoricoxib 90 mg; Drug: Part 2: Placebo to Etoricoxib 60 mg; Drug: Part 2: Placebo to Etoricoxib 90 mg
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: LY2127399; Drug: Placebo every 4 weeks; Drug: Placebo every 2 weeks
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: LY2127399; Drug: Placebo every 4 weeks; Drug: Placebo every 2 weeks
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: fostamatinib; Drug: fostamatinib; Drug: placebo
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified March 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: LY2127399; Drug: Placebo every 2 weeks; Drug: Placebo every 4 weeks
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Acute Gout
Intervention: Drug: ACZ885
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Biological: Humira (adalimumab); Drug: Methotrexate (MTX)
Sponsors: Abbott; Abbott
Recruiting - verified December 2011 - Condition: Early Rheumatoid Arthritis
Interventions: Biological: adalimumab; Drug: methotrexate
Sponsors: Abbott; Abbott
Recruiting - verified February 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: Abatacept; Drug: Methotrexate; Drug: Abatacept Placebo; Drug: Methotrexate Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: Lupus Arthritis
Interventions: Drug: Laquinimod; Drug: Laquinimod; Other: Placebo
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified May 2012 - Condition: Arthritis, Psoriatic
Interventions: Drug: placebo; Drug: ustekinumab; Drug: ustekinumab; Drug: placebo; Drug: placebo; Drug: ustekinumab; Drug: ustekinumab; Drug: ustekinumab
Sponsors: Centocor, Inc.; Centocor, Inc.
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: SAR153191 (REGN88); Drug: placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis; Regeneron Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Arthritis; Arthritis, Rheumatoid; Autoimmune Diseases
Interventions: Drug: golimumab or placebo; Drug: golimumab; Drug: golimumab or placebo; Drug: golimumab; Drug: golimumab or placebo
Sponsors: Centocor, Inc.; Centocor, Inc.; Merck
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: Etanercept; Drug: Adalimumab
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012 - Condition: Juvenile Idiopathic Arthritis
Intervention: Other: Withdrawal of anti-TNF therapy
Sponsors: Children's Hospital Medical Center, Cincinnati; Children's Hospital Medical Center, Cincinnati; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified April 2012 - Conditions: Psoriasis; Arthritis, Psoriatic
Interventions: Biological: ustekinumab; Biological: Biological therapies other than infliximab and ustekinumab; Drug: conventional systemic agents; Biological: infliximab
Sponsors: Centocor Ortho Biotech Services, L.L.C.; Centocor Ortho Biotech Services, L.L.C.
Recruiting - verified May 2012 - Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Conditions: Arthritis, Rheumatoid; Osteoarthritis
Interventions: Drug: celecoxib; Drug: Ibuprofen; Drug: Naproxen
Sponsors: Pfizer; Pfizer; The Cleveland Clinic
Recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: Lovastatin; Device: Lovastatin placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); Autoimmunity Centers of Excellence
Recruiting - verified September 2011
 |
Join Clinical Trials in Alabama for Arthritis |
